Background. Conventional peritoneal dialysis fluids (PDF) have been shown to compromise the function of both leukocytes and human peritoneal mesothelial cells (HPMC). Various in vitro studies have identified the low initial pH in combination with high lactate content, as well as the hyperosmolality and high glucose concentration present in currently used solutions as the primary determinants of their bioincompatibility. Bicarbonate buffered PDF (at neutral pH) display improved in vitro biocompatibility as compared to conventional, lactate buffered PDF. However, little information is currently available regarding the potential impact of PDF on the function of human peritoneal fibroblasts (HPFB), the major cell population present in peritoneal interstitium.
The peritoneal dialysis solution constitutes the primary treatment/patient interface in chronic peritoneal dialysis, as the peritoneal membrane of a patient undergoing continuous ambulatory peritoneal dialysis (CAPD) is exposed to approximately 3,000 liters per year of dialysis fluid. While recent years have seen various improvements in systems and techniques for fluid delivery and exchange, the composition of the solutions routinely used for peritoneal dialysis has not changed during the past two decades, despite the fact that their composition is unphysiological in two repects: (1) lactate is employed as the standard buffer system by which the pH of PDF is adjusted from pH 5.2 to pH 5.5 in order to prevent glucose caramelization during the industrial heat sterilization process; (2) glucose is present in high concentrations as the osmotic agent resulting in a strong hyperosmolality of the PDF in order to create an ultrafiltration gradient.
As a consequence, the repeated exposure of the peritoneal membrane of PD patients to solutions with unphysiological composition has raised questions as to the potential acute and long-term biocompatibility of PDF.
The first in vitro biocompatibility studies of PDF date back to 1981 when Duwe, Vas and Weatherhead reported that both low pH and hyperosmolality of commercial lactate-buffered PD fluids inhibit leukocyte functions such as phagocytosis, bactericidal activity, and chemiluminescence [1] . Since then, a rapidly growing number of in vitro studies with PD fluids has been published, virtually all of which agree that the combination of lactate and acidic pH adversely affect the function of both leukocytes and peritoneal mesothelial cells (Table 1) [reviewed in [21] [22] [23] . In addition, few ex vivo studies in humans [24, 25] and in vivo experiments using animal models [26 -30] have further supported the concept that conventional acidic PDF are indeed bioincompatible.
Although the relevance of these findings in terms of acute and long-term clinical consequences for the patients undergoing CAPD remains to be established, the multitude and severity of adverse effects that have been demonstrated has impelled both clinical scientists as well as the manufacturers of dialysis fluids to explore and develop alternatives for the currently used solutions. A primary focus in this respect has been the development of solutions with neutral pH as a first and seemingly logical approach to improve PDF biocompatibility. Bicarbonate, which constitutes a major physiological buffer system in body fluids, had been used for many years now as the gold standard in hemodialysis. Now that the technical problems associated with its use as the buffer system in peritoneal dialysis (such as, necessity of two-chamber bags; stabilization of pH very close to neutral range, that is, 7.4 Ϯ 0.2, to prevent excessive PCO 2 ) have been solved, several companies have developed bicarbonate-buffered PDF, some of which are currently undergoing clinical trials (Table 2 ). In addition, some authors have proposed using histidine- [36] or pyruvate-buffered dialysis solutions [37] [38] [39] ; however, these proposals have not been widely tested in clinical trials thus far.
Parallel to clinical safety and feasibility studies, the newly formulated bicarbonate-buffered solutions are presently undergoing a multifaceted approach to establish their biocompatibility properties. In addition to the evaluation of their impact on leukocyte functions, increasing attention is focused on their effect on peritoneal membrane cells such as mesothelial cells and fibroblasts. Both peritoneal mesothelial cells, constituting the superficial cell layer of the peritoneal membrane, and peritoneal fibroblasts, constituting the major cell population of peritoneal interstitium, possess a large biosynthetic repertoire for immunologically active molecules including cytokines and prostaglandins [40 -49] . Consequently, their potentially important role in peritoneal host defence appears to be established [50, 51] . While various investigations of the effect of (conventional and alternative) PDF on mesothelial cells have been published in recent years [19, 20, 52, 53] , only scant information is currently available regarding the effect of dialysis solutions on peritoneal fibroblasts. The current study therefore investigated the effect of bicarbonate-and lactate-buffered PDF on cultured human peritoneal cells, thereby comparing mesothelial cells and fibroblasts. The results of this study suggest that, while bicarbonate buffered PDF are less inhibitory to both peritoneal cell populations as compared to conventional, lactate buffered PDF, the peritoneal fibroblasts appear to be less susceptible to PDF toxicity than the peritoneal mesothelium.
METHODS
All chemicals were obtained from Sigma (Deisenhofen, Germany) unless otherwise stated. Crude trypsin was from Difco (Detroit, MI, USA). The culture vessels ( [20] Abbreviations are in the Appendix. Germany). The composition of these solutions is indicated in Table 3 .
Peritoneal cell culture
Human peritoneal mesothelial cells and fibroblasts were cultured from human omentum essentially as described previously [48, 54] . Briefly, the fibroblasts were cultured in a humidified atmosphere, 5% CO 2 -95% air at 37°C, with Ham's F12 medium (ICN/Flow, Meckenheim, Germany), the mesothelial cells in M 199 medium (ICN/Flow). Culture media were supplemented with penicillin (100 U/ml), streptomycin (100 g/ml), L-glutamine (2 mM), insulin (0.5 g/ml), transferrin (0.5 g/ml), hydrocortisone (0.4 g/ml); HEPES buffer (0.15 M; Gibco BRL, Berlin, Germany) and 10% vol/vol fetal calf serum (Gibco BRL). The pH was adjusted from 7.3 to 7.4 by adding 1 M NaOH.
Human omental tissue was obtained from consenting patients undergoing abdominal surgery. Omental specimens were washed ϫ3 in phosphate buffered saline (PBS; Biochrom, Berlin, Germany) and pieces of approximately 10 cm 2 were incubated in 15 ml trypsin/EDTA/glucose (0.125%/0.01%/0.1 wt/vol in PBS) for 20 minutes at 37°C. The suspension was centrifuged at 180 ϫ g and 4°C for five minutes. The remaining tissue and trypsin/EDTA/glucose solution were removed and the pelleted cells were washed twice (180 ϫ g at 4°C for 5 min) in cell culture medium containing 10% FCS to inhibit the trypsin activity. The trypsin/EDTA digestion was repeated once for 20 minutes followed by two more digestion steps of 40 minutes each. The cells obtained during each disaggregation step were resuspended in 5 ml cell culture medium and transferred to 25 cm 2 culture flasks. The enzymatic disaggregation of human omentum yielded homogeneous mesothelial cells during the first incubation period and caused an increasing release of fibroblasts during further trypsin/EDTA/glucose treatment. From the third cycle HPFB were harvested without contamination of mesothelial and other cells, as assessed by phase contrast microscopy. Immunofluorescence staining of routine HPFB cultures characterized these cells by their positive staining for vimentin and the absence of staining for cytokeratin 18, factor VIII and desmin while HPMC stained positive for for cytokeratin 18.
The primary cultures were incubated at 37°C, the medium was exchanged after 24 hours for the first time and every third day thereafter. Confluent cell cultures were subcultured with trypsin/EDTA/glucose solution (0.125%/ 0.01%/0.1%, wt/vol). The detachment of cells was observed by light microscopy and the trypsin activity inhibited by adding FCS supplemented culture medium thereafter. The cells were washed twice in FCS supplemented culture medium and seeded into new culture flasks at 1 ⁄3 of the density of the previous culture. For the incubation experiments HPFB and HPMC were grown to confluence in 24-well plates and growth arrested in cell culture medium with 0.1% FCS for 48 hours. Previous experiments had established that under these culture conditions both HPFB and HPMC remain in a viable, but nonproliferative state for at least 72 hours [48, 54] .
Incubation experiments with PDF
Confluent, nonproliferative HPFB monolayers were incubated at 5% CO 2 and 37°C for 15, 30, 45, 60, 75, and 90 minutes in the presence of test PDF, confluent nonproliferative HPMC were exposed to PDF at 37°C for 15, 30, 45 and 60 minutes. Control measurements after up to 90 minutes preincubation showed that the pH of bicarbonatebuffered fluids did not increase to above pH 7.6 under these conditions. At the indicated time intervals the cell supernatants were replaced by cell culture medium (0.1% FCS) containing 100 pg/ml recombinant human interleukin-1 beta (IL-1␤) for 24 hours. Following this recovery/ stimulation period, cell supernatants were harvested, centrifuged at 3000 ϫ g and stored at Ϫ20°C until further analysis. Parallel dose-response experiments were run stimulating HPFB with IL-1␤ for 24 hours in the presence of PDF diluted [(vol/vol) (1:1) to (1:5)] with culture medium containing 0.1% FCS. Incubation of HPFB or HPMC with recombinant IL-1␤ (100 pg/ml) for up to 48 hours did not affect cell viability or the levels of total cellular protein as compared to cells treated with medium alone (data not shown).
Enzyme immunoassay for interleukin-6
Interleukin-6 (IL-6) in cell supernatants was determined as described previously [9] . Briefly, the enzyme immunoassay for IL-6 employed microtiter strips (Nunc, Wiesbaden, Germany) coated with an affinity-purified polyclonal rabbit anti-mouse IgG antibody (Dakopatts, Hamburg, Germany) followed by a mouse monoclonal anti-human IL-6 antibody (Serva, Heidelberg, Germany). IL-6 in samples and standards was detected by a sequence of incubations with: (i) a polyclonal anti-human IL-6 antibody coupled to biotin (R&D Systems, Minneapolis, MN, USA); (ii) horseradish peroxidase-streptavidin (Calbiochem, Frankfurt, Germany); and (iii) tetramethyl benzidine substrate buffer for color development (Fluka, Buchs, Switzerland). The IL-6 content of the samples was calculated from a standard curve using recombinant human IL-6 standards (Janssen, Beerse, Belgium) ranging from 20 to 2,000 pg/ml. The lower detection limit of the assay was 20 pg/ml. No cross-reactivity with recombinant TNF␣, TNF␤, IL-1␣, IL-1␤, IL-2, IL-3 or IL-4 was observed when these cytokines were added to blank samples in concentrations up to 50 ng/ml (recombinant cytokines were obtained from British Biotechnology, Oxford, UK).
Statistical analysis
All statistical analyses were performed using the Wilcoxon signed-ranks matched-pairs test for non-parametric data. A two-sided P value of less than 0.05 was considered as being significant. All data are presented as mean Ϯ SEM.
RESULTS

Interleukin-6 release from peritoneal fibroblasts preexposed to dialysis fluids: Time course experiments
Control HPFB preincubated (15 to 90 min) in culture medium released between 2588 Ϯ 235 pg/ml (mean Ϯ SEM; at 30 min) and 3419 Ϯ 524 pg/ml IL-6 (at 90 min) following stimulation (24 hr) with IL-1␤ (100 pg/ml). Neither with cells pre-exposed for up to 90 minutes to lactate-buffered acidic PDF (Fig. 1A) , nor with cells incubated in bicarbonate-buffered neutral PDF (Fig. 1B) was a significant reduction of IL-1␤ driven IL-6 secretion observed, irrespective of the glucose concentration. 
Interleukin-6 release from peritoneal mesothelial cells pre-exposed to dialysis fluids: Time course experiments
Control HPMC preincubated (15 to 60 min) in culture medium released (mean Ϯ SEM) between 1479 Ϯ 394 pg/ml (at 45 min) and 1940 Ϯ 569 pg/ml IL-6 (at 60 min) following subsequent of stimulation (24 hr) with IL-1␤ (100 pg/ml). With both low-and high-glucose containing lactatebuffered PDF, a significant reduction of IL-1␤ driven IL-6 secretion from HPMC was observed following pre-exposure periods of 30 minutes and longer ( Fig. 2A) . In contrast, a significant IL-6 inhibition with low-and high glucose containing bicarbonate-buffered PDF was evident only after 60 minutes of preincubation (Fig. 2B) . No significant difference between the two glucose concentrations could be detected with either buffer system.
Interleukin-6 release from peritoneal fibroblasts coincubated in dialysis fluids: Dose response experiments
HPFB stimulated with IL-1␤ (100 pg/ml) for 24 hours in the presence of low glucose-containing lactate-buffered PDF showed a significant IL-6 suppression with dilutions of 1:1 and 1:2 (vol/vol), which was normalized with dilutions of 1:3 and above (Fig. 3A) . With high glucose-containing lactate-buffered PDF, a significant inhibition of HPFB IL-6 secretion was observed even in higher dilutions of 1:3 and 1:5 (Fig. 3B) . With low glucose-containing bicarbonate-buffered PDF, a significant effect on IL-6 secretion was only evident in the 1:1 dilution, whereas cells exposed to dilutions of 1:2 and higher showed a normal IL-6 response (Fig. 3C ). Likewise, with high glucose-containing bicarbonate-buffered PDF the IL-6 inhibition was reversed with dilutions of 1:3 and above (Fig. 3D ).
DISCUSSION
Most previous biocompatibility studies of newly developed, neutral peritoneal dialysis fluids have employed leukocytes that were acutely exposed in vitro to dialysis fluids followed by the assessment of one or several cell functional parameters. These static procedures, however, do not resemble the in vivo situation of CAPD where a dynamic process of fluid equilibration and peritoneal leukocyte turnover is known to occur during the dialysis cycle. As a consequence, cells are exposed in vivo to a very low pH (ϽpH 6.0) only for few minutes, whereas some in vitro studies used exposure periods of many hours, depending on the test system employed. As an alternative, preincubation/ recovery systems have been developed in which the cells were pre-exposed to test fluids only briefly, followed by a recovery period in a balanced medium during (or at the end of) which the cell functional parameters were assessed. For both types of in vitro experiments, various leukocyte populations have been employed. Peritoneal macrophages (PMØ) or polymorphonuclear leukocytes (PMN) were harvested from the peritoneal effluent of CAPD patients. While peritoneal leukocytes appear to be an obvious relevant target for PDF biocompatibility studies, their use is also associated with certain drawbacks. As a rule, the number of cells available, at least in the effluent of noninfected patients, is relatively low, resulting in certain limits to the type, number and feasibility of in vitro experiments. In addition, cells isolated from peritoneal effluent have already been exposed to dialysis fluids in vivo that may potentially influence the results of subsequent in vitro experimentation. Alternatively, peripheral blood mononuclear cells (PBMC) and PMN isolated from the blood of healthy donors or uremic patients have been studied. Since these cells are the circulating precursors of PMØ and peritoneal PMN they are generally accepted as valid test systems for PDF biocompatibility studies. It has to be kept in mind, however, that peripheral blood leukocytes may differ from peritoneal cells with regard to the expression of surface antigens and key mediator substances, including cytokines and their antagonists, since these properties are reportedly associated with the state of cell differentiation/ maturity [55] . Moreover, their sensitivity to the unphysiological components of PDF such as pH or osmotic stress may be different.
Finally, a wide range of parameters has been employed to substantiate the potential impact of PDF on cell function, including cell respiration/respiratory burst/superoxide production, phagocytosis and bacterial killing, intracellular pH, intracellular ATP levels, cytokine mRNA expression and secretion, and actin polymerization (Tables 1 and 4) .
Despite this large variability outlined above regarding cell populations, experimetal procedures and target parameters used for in vitro biocompatibility testing, virtually all studies published to date agree that: (i) conventional, lactate-buffered acidic PDF adversely affect in vitro leukocyte function; and (ii) leukocyte function may be restored, at least partially, by use of alternative neutral PDF irrespective of the buffer system used (Table 4 ). This view is further supported by emerging ex vivo studies in CAPD patients indicating that in vivo exposure of PMØ to bicarbonate/lactate-buffered PDF or bicarbonate-buffered PDF improves their subsequent ability to secrete TNF␣ [71] .
More recently, research interest has focused on the effect of PDF on resident peritoneal membrane cells such as mesothelial cells and fibroblasts, since their repeated exposure to bioincompatible solutions might, at least theoretically, impact on the long-term function of the peritoneal membrane as a dialyzing organ. Earlier work by Witowski et al indicated that a short (15 to 30 min) pre-exposure of HPMC to lactate-buffered acidic PDF resulted in a significant inhibition of their IL-1␤ driven IL-6 secretion, which was reversed when the solution was neutralized [20] . Using a similar experimental setup, Topley et al recently showed that both bicarbonate-buffered [53] or bicarbonate/lactatebuffered [52] neutral solutions did not significantly interfere with HPMC intracellular ATP levels or IL-1␤ driven IL-6 secretion, both of which were significantly reduced by conventional acidic PDF.
In contrast to these emerging data on the effect of alternative neutralized PDF on peritoneal mesothelial cells, virtually no information has been available to date regarding the potential impact of these fluids on peritoneal fibroblast function. Since HPFB not only constitute the major cell population of peritoneal interstitium, but also were shown to be substantially involved in the peritoneal cytokine network regulating peritoneal inflammation [47] [48] [49] , the current study investigated the effect of alternative, neutral PDF versus conventional, acidic PDF, on peritoneal fibroblasts compared to peritoneal mesothelial cells, using an in vitro experimental setup that has been previously established for the evaluation of PDF effects on HPMC function [52, 53] .
Short (30 min) pre-exposure to lactate-buffered PDF significantly reduced the IL-1␤-stimulated IL-6 release from HPMC during a subsequent recovery period (24 hr) in culture medium, while exposure to bicarbonate-buffered, neutral PDF resulted in a significant inhibition of HPMC IL-6 secretion only after a prolonged (Ն60 min) exposure. In contrast, neither lactate-buffered acidic PDF nor bicarbonate-buffered neutral PDF significantly affected IL-1␤-stimulated IL-6 secretion irrespective of the glucose concentration when HPFB were pre-exposed for up to 90 [70] minutes to these solutions, suggesting that HPFB may be more resistant than HPMC to the unphysiological properties of peritoneal dialysis solutions. Additional coincubation, dose-response experiments with dilutions of lactate or bicarbonate buffered PDF indicated, however, that prolonged exposure to dialysis fluids may lead to an inhibition of HPFB IL-6 secretion in a dose-dependent fashion. In this coincubation system the high glucose-containing PDF showed stronger effects than their low glucose counterparts, and the bicarbonate buffered solutions were generally less inhibitory as compared to the lactate buffered PDF when tested at the same dilution. This finding is of particular interest, since in higher dilutions the pH of the lactate buffered PDF was neutralized by the addition of cell culture medium. Thus, the differences outlined above cannot only be explained by the different acidity, glucose content and hyperosmolality of the solution. Thus, a hypothetical explanation may be the lesser presence in bicarbonate buffered fluids of additional potentially toxic factors such as glucose degradation products (GDP) [72] [73] [74] [75] . Since the amount of GDP produced during heat sterilization of glucose solutions is dependent not only on the glucose concentration but also on the pH at which the sterilization process takes place, their concentration is significantly lower in bicarbonate buffered solutions where the glucose is contained in a separate compartment at a very low pH [76, 77] , whereas conventional PDF regularly contain high GDP concentrations [78] . Taken together, the results of the current study add further evidence to support the notion that bicarbonatebuffered, neutral peritoneal dialysis fluids offer improved biocompatibility properties as compared to conventional, acidic lactate-buffered solutions. The issue of whether the type of buffer per se influences cell function remains less well characterized. Overall, it appears that bicarbonate buffered fluids improve cell function irrespective of their composition (such as, bicarbonate alone, bicarbonate/lactate, or bicarbonate/glycylglycine); however, a few studies also indicate that, particularly in the presence of high glucose concentrations, bicarbonate buffered solutions may preserve cell function better than an otherwise identical, pH neutral lactate-buffered solution [53, 59] . This area quite clearly requires further investigation.
The general question that remains to be answered is the issue of the potential biological relevance of the improved in vitro biocompatibility of the neutral dialysis solutions. In terms of acute effects this would culminate in the question of whether the improved phagocyte, HPMC and HPFB function will, for example, lead to a reduction of peritonitis rates, or, alternatively, if the incidence of infectious complications will be increased due to an improved survival of microorganisms in biocompatible fluids. The clinical studies performed thus far or that are currently underway do not systematically address this question. However, as far as initial observations go, a major difference in peritonitis rates between alternative and conventional solutions has not yet been observed [31] [32] [33] [34] [35] . An important issue regarding long-term outcome will be the potential impact of the dialysis fluids on the incidence of peritoneal sclerosing syndromes and ultrafiltration failure. Quite clearly, answers to these questions can only be provided by controlled, randomized and prospective clinical trials of alternative versus conventional solutions. Such trials will, however, require a large number of patients studied longitudinally for several years before final conclusive results will be available. In addition, it should not be forgotten that avoiding PDF acidity may help to resolve only part of the PDF bioincompatibility problem since an optimal osmotic agent, both avoiding the metabolic effects as well as the potential cytotoxicity of high glucose concentrations, is not yet available. The achievement of physiological pH, however, constitutes a realistic short-term goal that appears to be well substantiated by the evidence published to date, and, at least in the case of solutions manufactured in two-compartment bags, may at the same time minimize the potential problems associated with glucose degradation products. It is thus to be expected that as soon as they are available on a regular basis, and provided that their use is also economically viable, the neutral PD fluids with alternative buffer systems will be utilized widely even before conclusive clinical data are available.
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